BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33450762)

  • 1. Temperature-dependent autoactivation associated with clinical variability of PDGFRB Asn666 substitutions.
    Bredrup C; Cristea I; Safieh LA; Di Maria E; Gjertsen BT; Tveit KS; Thu F; Bull N; Edward DP; Hennekam RCM; Høvding G; Haugen OH; Houge G; Rødahl E; Bruland O
    Hum Mol Genet; 2021 Mar; 30(1):72-77. PubMed ID: 33450762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a progeria-like condition in the severe end of Penttinen syndrome.
    Bredrup C; Stokowy T; McGaughran J; Lee S; Sapkota D; Cristea I; Xu L; Tveit KS; Høvding G; Steen VM; Rødahl E; Bruland O; Houge G
    Eur J Hum Genet; 2019 Apr; 27(4):574-581. PubMed ID: 30573803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Point Mutation in PDGFRB Causes Autosomal-Dominant Penttinen Syndrome.
    Johnston JJ; Sanchez-Contreras MY; Keppler-Noreuil KM; Sapp J; Crenshaw M; Finch NA; Cormier-Daire V; Rademakers R; Sybert VP; Biesecker LG
    Am J Hum Genet; 2015 Sep; 97(3):465-74. PubMed ID: 26279204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDGFRB mutation causes autosomal-dominant Penttinen syndrome.
    Aminkeng F
    Clin Genet; 2015 Dec; 88(6):531. PubMed ID: 26507258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Premature Aging Syndrome, Penttinen Type: Report of a Chinese Case with a PDGFRB Mutation.
    Zhang Z; Zheng S; Zheng S; Wang Y; Xu XG; Gao XH; Chen HD
    Acta Derm Venereol; 2018 Oct; 98(9):912-913. PubMed ID: 29944170
    [No Abstract]   [Full Text] [Related]  

  • 6. Expansion of the phenotype of Kosaki overgrowth syndrome.
    Minatogawa M; Takenouchi T; Tsuyusaki Y; Iwasaki F; Uehara T; Kurosawa K; Kosaki K; Curry CJ
    Am J Med Genet A; 2017 Sep; 173(9):2422-2427. PubMed ID: 28639748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penttinen syndrome-associated PDGFRB Val665Ala variant causes aberrant constitutive STAT1 signalling.
    Nédélec A; Guérit EM; Dachy G; Lenglez S; Wong LS; Arts FA; Demoulin JB
    J Cell Mol Med; 2022 Jul; 26(14):3902-3912. PubMed ID: 35689379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First case report of Penttinen syndrome from India.
    Aggarwal B; Correa ARE; Gupta N; Jana M; Kabra M
    Am J Med Genet A; 2022 Feb; 188(2):683-687. PubMed ID: 34799960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Pellino-2 variant is associated with constitutive NLRP3 inflammasome activation in a family with ocular pterygium-digital keloid dysplasia.
    Cristea I; Abarca H; Christensen Mellgren AE; Trubnykova M; Mehrasa R; Peters DJM; Houge G; Hennekam RCM; Rødahl E; Bruland O; Bredrup C
    FEBS Lett; 2023 May; 597(9):1290-1299. PubMed ID: 36776133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome.
    Iznardo H; Bredrup C; Bernal S; Gladkauskas T; Mascaró JM; Roé E; Baselga E
    Am J Med Genet A; 2022 Apr; 188(4):1233-1238. PubMed ID: 34894066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Master of Puppets: Pleiotropy of PDGFRB and its Relationship to Multiple Diseases.
    Moura DAP; de Oliveira JRM
    J Mol Neurosci; 2020 Dec; 70(12):2102-2106. PubMed ID: 32613555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Segmental overgrowth and aneurysms due to mosaic PDGFRB p.(Tyr562Cys).
    Chenbhanich J; Hu Y; Hetts S; Cooke D; Dowd C; Devine P; ; Russell B; Kang SHL; Chang VY; Abla AA; Cornett P; Yeh I; Lee H; Martinez-Agosto JA; Frieden IJ; Shieh JT
    Am J Med Genet A; 2021 May; 185(5):1430-1436. PubMed ID: 33683022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acro-osteolysis, keloid like-lesions, distinctive facial features, and overgrowth: two newly recognized patients with premature aging syndrome, Penttinen type.
    Zufferey F; Hadj-Rabia S; De Sandre-Giovannoli A; Dufier JL; Leheup B; Schweitze C; Bodemer C; Cormier-Daire V; Le Merrer M
    Am J Med Genet A; 2013 Jul; 161A(7):1786-91. PubMed ID: 23720404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT1 modulates tissue wasting or overgrowth downstream from PDGFRβ.
    He C; Medley SC; Kim J; Sun C; Kwon HR; Sakashita H; Pincu Y; Yao L; Eppard D; Dai B; Berry WL; Griffin TM; Olson LE
    Genes Dev; 2017 Aug; 31(16):1666-1678. PubMed ID: 28924035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kosaki overgrowth syndrome: A newly identified entity caused by pathogenic variants in platelet-derived growth factor receptor-beta.
    Takenouchi T; Okuno H; Kosaki K
    Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):650-657. PubMed ID: 31710779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrastructural skin changes in Egyptian mandibuloacral dysplasia patients with p.Arg527Leu LMNA mutation and in their asymptomatic heterozygotic mothers.
    Al-Haggar M; Shams A; Madej-Pilarczyk A; Barakat T; Puzianowska-Kuznicka M
    J Clin Pathol; 2013 Nov; 66(11):1000-4. PubMed ID: 23775434
    [No Abstract]   [Full Text] [Related]  

  • 17. Ocular pterygium--digital keloid dysplasia.
    Abarca H; Mellgren AE; Trubnykova M; Haugen OH; Høvding G; Tveit KS; Houge G; Bredrup C; Hennekam RC
    Am J Med Genet A; 2014 Nov; 164A(11):2901-7. PubMed ID: 25124224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel de novo PDGFRB variant in a child with severe cerebral malformations, intracerebral calcifications, and infantile myofibromatosis.
    Guimier A; Gordon CT; Hully M; Blauwblomme T; Minard-Colin V; Bole-Feysot C; Nitschké P; Oufadem M; Boddaert N; Sarnacki S; Amiel J
    Am J Med Genet A; 2019 Jul; 179(7):1304-1309. PubMed ID: 31004414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A patient with germ-line gain-of-function PDGFRB p.N666H mutation and marked clinical response to imatinib.
    Pond D; Arts FA; Mendelsohn NJ; Demoulin JB; Scharer G; Messinger Y
    Genet Med; 2018 Jan; 20(1):142-150. PubMed ID: 28726812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy.
    Wenger TL; Bly RA; Wu N; Albert CM; Park J; Shieh J; Chenbhanich J; Heike CL; Adam MP; Chang I; Sun A; Miller DE; Beck AE; Gupta D; Boos MD; Zackai EH; Everman D; Ganapathi S; Wilson M; Christodoulou J; Zarate YA; Curry C; Li D; Guimier A; Amiel J; Hakonarson H; Webster R; Bhoj EJ; Perkins JA; Dahl JP; Dobyns WB
    Am J Med Genet A; 2020 Jul; 182(7):1576-1591. PubMed ID: 32500973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.